Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors

Many different growth factor ligands, including epidermal growth factor (EGF) and the neuregulins (NRGs), regulate members of the erbB/HER family of receptor tyrosine kinases. These growth factors induce erbB receptor oligomerization, and their biological specificity is thought to be defined by the combination of homo‐ and hetero‐oligomers that they stabilize upon binding. One model proposed for ligand‐induced erbB receptor hetero‐oligomerization involves simple heterodimerization; another suggests that higher order hetero‐oligomers are ‘nucleated’ by ligand‐induced homodimers. To distinguish between these possibilities, we compared the abilities of EGF and NRG1‐β1 to induce homo‐ and hetero‐oligomerization of purified erbB receptor extracellular domains. EGF and NRG1‐β1 induced efficient homo‐oligomerization of the erbB1 and erbB4 extracellular domains, respectively. In contrast, ligand‐induced erbB receptor extracellular domain hetero‐oligomers did not form (except for s‐erbB2–s‐erbB4 hetero‐oligomers). Our findings argue that erbB receptor extracellular domains do not recapitulate most heteromeric interactions of the erbB receptors, yet reproduce their ligand‐induced homo‐oligomerization properties very well. This suggests that mechanisms for homo‐ and hetero‐oligomerization of erbB receptors are different, and contradicts the simple heterodimerization hypothesis prevailing in the literature.

[1]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[2]  Yosef Yarden,et al.  Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.

[3]  M. Sliwkowski,et al.  Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.

[4]  M. Waterfield,et al.  Epidermal growth factor binding induces a conformational change in the external domain of its receptor. , 1989, The EMBO journal.

[5]  Y. Yarden,et al.  The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions , 1997, FEBS letters.

[6]  H. P. Fell,et al.  HER4-mediated Biological and Biochemical Properties in NIH 3T3 Cells , 1996, The Journal of Biological Chemistry.

[7]  J. Schlessinger,et al.  Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3. , 1988, The EMBO journal.

[8]  Y. Yarden,et al.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. , 1987, Biochemistry.

[9]  C. R. Middaugh,et al.  Statistical determination of the average values of the extinction coefficients of tryptophan and tyrosine in native proteins. , 1992, Analytical biochemistry.

[10]  A. Ullrich,et al.  EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. , 1991, The Journal of biological chemistry.

[11]  Y. Yarden,et al.  Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase , 1999, Oncogene.

[12]  Y. Yarden,et al.  Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. , 1990, Biochemistry.

[13]  A. Thomason,et al.  Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2 (*) , 1996, The Journal of Biological Chemistry.

[14]  D. Stern,et al.  Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  M. Greene,et al.  Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function , 1990, Cell.

[16]  Xin-Yuan Fu,et al.  Erbb4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation , 1999, The Journal of cell biology.

[17]  Y. Yarden,et al.  Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. , 1987, Biochemistry.

[18]  M. O’Connor-McCourt,et al.  The extracellular domain of the epidermal growth factor receptor. Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-domain mutant. , 1994, European journal of biochemistry.

[19]  Pedro Cuatrecasas,et al.  Local aggregation of hormone–receptor complexes is required for activation by epidermal growth factor , 1979, Nature.

[20]  T. Arakawa,et al.  Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3 (*) , 1995, The Journal of Biological Chemistry.

[21]  I. Lax,et al.  Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. , 1993, Biochemistry.

[22]  H. Jd,et al.  The current role and future prospects of paclitaxel in the treatment of small cell lung cancer. , 1999 .

[23]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.

[24]  A. Ullrich,et al.  Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells , 1990, Molecular and cellular biology.

[25]  J. Schlessinger SH2/SH3 signaling proteins. , 1994, Current opinion in genetics & development.

[26]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[27]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[28]  M. Klagsbrun,et al.  The Epidermal Growth Factor Receptor Couples Transforming Growth Factor-α, Heparin-binding Epidermal Growth Factor-like Factor, and Amphiregulin to Neu, ErbB-3, and ErbB-4* , 1996, The Journal of Biological Chemistry.

[29]  J. Schlessinger,et al.  Regulation of signal transduction and signal diversity by receptor oligomerization. , 1994, Trends in biochemical sciences.

[30]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[31]  M. Sliwkowski,et al.  Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. , 1994, The Journal of biological chemistry.

[32]  D. Engelman,et al.  Two EGF molecules contribute additively to stabilization of the EGFR dimer , 1997, The EMBO journal.

[33]  D. Stern,et al.  EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.

[34]  T. van Raaij,et al.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.

[35]  L. Cantley,et al.  A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.

[36]  W. Dougall,et al.  Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Sliwkowski,et al.  Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4 , 1998, FEBS letters.

[38]  C. Cantor,et al.  Biophysical Chemistry: Part II: Techniques for the Study of Biological Structure and Function , 1980 .

[39]  A. Ullrich,et al.  Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. , 1992, The Journal of biological chemistry.

[40]  C DeLisi,et al.  Interaction between proteins localized in membranes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Betzel,et al.  The secreted form of the epidermal growth factor receptor. Characterization and crystallization of the receptor-ligand complex. , 1990, The Journal of biological chemistry.

[42]  M. Eisenstein,et al.  Bivalence of EGF‐like ligands drives the ErbB signaling network , 1997, The EMBO journal.

[43]  P. Wyatt Light scattering and the absolute characterization of macromolecules , 1993 .

[44]  I. Friedberg,et al.  Secondary Dimerization between Members of the Epidermal Growth Factor Receptor Family* , 1997, The Journal of Biological Chemistry.

[45]  S. Hubbard,et al.  Autoregulatory Mechanisms in Protein-tyrosine Kinases* , 1998, The Journal of Biological Chemistry.

[46]  M. Weber,et al.  An Incomplete Program of Cellular Tyrosine Phosphorylations Induced by Kinase-defective Epidermal Growth Factor Receptors (*) , 1995, The Journal of Biological Chemistry.

[47]  A. Ullrich,et al.  Growth factor signaling by receptor tyrosine kinases , 1992, Neuron.

[48]  R. Epstein,et al.  Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction. , 1998, The Biochemical journal.

[49]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[50]  A. Ullrich,et al.  Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor. A low resolution projection structure of the ligand-binding domain. , 1991, The Journal of biological chemistry.

[51]  D. Stern,et al.  Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation , 1999, Oncogene.